On 30 January, Goodrich Petroleum Corp. (NYSE:GDP) announced year-end 2014 reserves and its revised preliminary 2015 capital expenditure budget. Goodrich Petroleum Corporation (the “Company”) reported proved reserves of 273.7 Bcfe as of December 31, 2014, with future net cash flow of $1.3 billion and present value of the future net cash flow before income taxes discounted at 10% (“PV-10”) of $650.6 million. On Monday shares of Goodrich Petroleum Corp. (NYSE:GDP) closed at $3.31. Company’s sales growth for last 5 years was -1.20% and EPS growth for next 5 years is recorded as 15.00%.
Equities researchers at Credit Suisse cut their target price on shares of Avon Products Inc. (NYSE:AVP) from $11.50 to $9.00 in a research report issued on Monday. The firm currently has a “neutral” rating on the stock. Credit Suisse’s price target indicates a potential upside of 10.84% from the company’s current price. Avon Products Inc. (NYSE:AVP) in last trading activity fell -1.35% to close at $8.76. Company weekly performance is 7.88% while its quarterly performance stands at -14.70%. Avon Products Inc. (NYSE:AVP) is -43.76% away from its 52 week high.
On 30 January, Tyco International Ltd. (NYSE:TYC) reported revenues of $917 million. Income from continuing operations fell to $0.38 from $0.52. Adjusted earnings per share from continuing operations were $0.49, while it totaled $0.42 last year. On last trading day Tyco International Ltd. (NYSE:TYC) advanced 0.46% to close at $41.76. Its volatility for the week is 1.71% while volatility for the month is 1.82%. TYC’s sales growth for past 5 years was -9.30% and its EPS growth for past 5 years was 19.50%. Tyco International Ltd. (NYSE:TYC) monthly performance is -4.66%.
On 29 January, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced it has appointed Mark Stephen Gelder, M.D. as Vice President, Clinical Development. Dr. Gelder will be responsible for planning and executing Inovio’s clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio’s Chief Medical Officer. On Monday shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) closed at $7.91. Company’s sales growth for last 5 years was 45.10% and EPS growth for next 5 years is recorded as 0.00%.
Silver Spring Networks, Inc. (NYSE:SSNI) reported fourth-quarter earnings of $501,000.
On a per-share basis, the Redwood City, California-based company said it had net income of 1 cent. Earnings, adjusted for one-time gains and costs, were 3 cents per share. For the year, the company reported that its loss narrowed to $89.2 million, or $1.84 per share. Revenue was reported as $191.3 million. On last trading day Silver Spring Networks, Inc. (NYSE:SSNI) fell -3.08% to close at $7.23. Its volatility for the week is 4.34% while volatility for the month is 3.76%. SSNI’s sales growth for past 5 years was 404.50% and its EPS growth for past 5 years was 24.50%. Silver Spring Networks, Inc. (NYSE:SSNI) monthly performance is -2.82%.